Review Article On "Human Metapneumovirus: A Hidden Threat in Respiratory Infections"

Shrishti Garg*[1], Mohammad Jalees*[2], Himani Joshi*[3]
[1,2] *Orlean College of Pharmacy, Knowledge Park III, Greater Noida*
[3]*Assistant Professor, Orlean College of Pharmacy, Knowledge Park III, Greater Noida*

Abstract: Herbal Human Metapneumovirus (HMPV) is an under-recognized viral pathogen that contributes significantly to respiratory infections, particularly in vulnerable populations such as young children, the elderly, and immunocompromised individuals. Discovered in 2001, HMPV is a member of the Paramyxoviridae family and shares clinical features with other common respiratory viruses, including respiratory syncytial virus (RSV) and influenza, often complicating its diagnosis. Despite its importance in the etiology of lower respiratory tract infections, HMPV remains a hidden threat due to its clinical overlap with other viral infections and a lack of widespread diagnostic awareness. This review aims to examine the pathophysiology, epidemiology, clinical manifestations, and challenges in diagnosing HMPV, as well as current management strategies. While there is no specific antiviral treatment for HMPV, supportive care remains the cornerstone of management, highlighting the urgent need for targeted therapies and vaccines. Further research into HMPV's clinical significance, diagnostic improvements, and the development of preventive measures is essential to mitigate its impact on public health.

Keywords: Human Metapneumovirus (HMPV), Respiratory virus, HMPV symptoms, HMPV treatment, HMPV diagnosis, HMPV prevention, Pediatric respiratory infections, HMPV transmission, HMPV epidemiology, HMPV in adults, HMPV pathogenesis, HMPV and pneumonia, HMPV vaccination, HMPV and COPD (Chronic Obstructive Pulmonary Disease), HMPV complications.

1. INTRODUCTION

Unveiling a Hidden Respiratory Threat

Respiratory infections are among the leading causes of illness and death worldwide, with viral pathogens being major contributors to the global burden of disease. Among these, well-known viruses like influenza, respiratory syncytial virus (RSV), and rhinoviruses often dominate clinical attention, while other viral agents, such as Human Metapneumovirus (HMPV), remain underappreciated and underdiagnosed. HMPV, a member of the Paramyxoviridae family, was first identified in 2001, yet its significance in respiratory infections has only recently gained broader recognition. [3]

HMPV is a negative-sense RNA virus that shares similarities with RSV, often leading to symptoms such as fever, cough, wheezing, and nasal congestion, primarily affecting the upper and lower respiratory tracts. This overlap in clinical symptoms with other respiratory pathogens has resulted in the virus being frequently misdiagnosed or underdiagnosed, making it a "hidden" threat in respiratory medicine. HMPV is known to cause both mild respiratory illnesses and more severe conditions, including bronchiolitis, pneumonia, and exacerbations of pre-existing respiratory conditions, particularly in infants, elderly individuals, and those with compromised immune systems.

Epidemiologically, HMPV infections are most prevalent in the winter and spring months, often in temperate regions, but their burden Is likely underestimated due to limited diagnostic testing and lack of widespread awareness. In children under the age of 5, HMPV has been identified as one of the leading causes of viral respiratory infections requiring hospitalization, alongside RSV and influenza. Despite the widespread occurrence of HMPV infections, the lack of specific antiviral therapies and vaccines underscores the need for greater focus on this pathogen in both clinical and research settings. [1]

In terms of pathophysiology, HMPV infects the respiratory epithelium, leading to inflammation and obstruction in the airways. Severe cases can result in acute respiratory distress syndrome (ARDS) and other life-threatening complications, especially in vulnerable populations. Furthermore, HMPV's ability to co-infect with other viruses complicates clinical diagnosis, often resulting in the failure to identify it as the primary pathogen in co-infected patients. [2]

Although significant progress has been made in understanding the molecular biology and

epidemiology of HMPV, many gaps remain in terms of diagnostic methods, treatment strategies, and preventive measures. This review will explore the pathophysiology, epidemiology, clinical manifestations, diagnostic challenges, and current management of HMPV infections. By shedding light on the significance of this often-overlooked pathogen, we aim to promote a deeper understanding of its role in respiratory diseases and to advocate for improved clinical awareness, diagnostic approaches, and the development of vaccines and antiviral treatments.

2. THE VIROLOGY OF HMPV: UNDERSTANDING THE VIRUS BEHIND THE SYMPTOMS

Human Metapneumovirus (hMPV) is a member of the Paramyxoviridae family, specifically classified within the Metapneumovirus genus. This family also includes other notable respiratory pathogens like Respiratory Syncytial Virus (RSV) and Human Parainfluenza Viruses (HPIVs). hMPV was first identified in 2001 after the detection of viral RNA in patients with respiratory infections.

The virus has a negative-sense, single-stranded RNA genome, typical of other members of the Paramyxoviridae family. The genome of hMPV is approximately 13.2 kilobases in length and encodes for eight genes, which are responsible for producing viral proteins that facilitate the virus's replication and its ability to evade the host immune system. These proteins include the fusion (F) protein, which plays a crucial role in viral entry into host cells, and the hemagglutinin-neuraminidase (HN) protein, involved in the release of the virus from infected cells.

Structure: hMPV particles are roughly spherical, measuring about 150 to 200 nm in diameter. The virus has an envelope derived from the host cell membrane, and its outer surface is studded with the F and HN proteins, essential for its interaction with the host's cellular machinery.

Transmission and Pathogenesis:

hMPV is primarily transmitted via aerosolized respiratory droplets produced when an infected person coughs or sneezes, as well as by direct contact with contaminated surfaces. The virus primarily infects the upper and lower respiratory tracts, causing symptoms ranging from mild upper respiratory illness to severe pneumonia, particularly in vulnerable populations such as infants, the elderly, and immunocompromised individuals.

The virus initially enters the body through the nasopharyngeal mucosa, where the F protein facilitates fusion with the host cell membrane, allowing the virus to release its RNA into the host cell. Once inside, the virus hijacks the host cell's machinery to replicate and produce viral proteins. The virus replicates primarily in the epithelial cells of the respiratory tract, causing local inflammation and contributing to the symptoms of congestion, cough, and wheezing.

In severe cases, especially in infants and immunocompromised patients, lower respiratory tract involvement can lead to conditions like bronchiolitis and pneumonia, where the inflammation of the lung airways and alveoli can result in respiratory distress.[4]

3. CLINICAL IMPACT: RECOGNIZING THE SPECTRUM OF HMPV INFECTIONS

Human metapneumovirus (hMPV) is an important cause of respiratory illness, particularly during the colder months. The virus has a broad clinical spectrum, affecting a wide range of age groups. However, its impact is most significant in vulnerable populations, including young children, older adults, and immunocompromised individuals.[5]

3.1 hMPV and Pediatric Populations

In children, particularly those under the age of 2, hMPV is a leading cause of respiratory tract infections, second only to respiratory syncytial virus (RSV) in some regions. It can cause a spectrum of illness, ranging from mild upper respiratory symptoms to severe bronchiolitis and pneumonia. In fact, hMPV is often identified as a primary cause of bronchiolitis in infants, contributing to substantial hospitalization rates. The clinical presentation in children typically includes cough, wheezing, fever, and nasal congestion, and in severe cases, it can result in respiratory failure and the need for intensive care.

3.2 hMPV in the Elderly

The elderly, especially those aged 65 years and older, are particularly susceptible to severe outcomes from

hMPV infection. This age group often experiences more severe illness, with increased rates of hospitalization, respiratory distress, and mortality. The presence of underlying chronic conditions, such as chronic obstructive pulmonary disease (COPD) or heart disease, can exacerbate the severity of the infection, leading to significant complications. In some cases, hMPV infections in elderly patients are associated with prolonged recovery times, increased risk of secondary infections, and the need for mechanical ventilation.[7]

3.3 Immunocompromised Individuals

Immunocompromised individuals, including those undergoing organ transplants, chemotherapy, or immunosuppressive therapy, are at heightened risk for severe hMPV infections. Due to their weakened immune systems, these patients often experience longer durations of illness and are more likely to develop complications such as secondary bacterial infections or respiratory failure. In some cases, hMPV infections in these patients can be fatal. Research indicates that the immunocompromised population is especially vulnerable to prolonged viral shedding, which increases the risk of transmission and further simultaneously. [6]

Clinical Features and Impact on Health Systems

hMPV typically presents with clinical features that overlap with other viral respiratory infections, such as RSV and influenza, including cough, wheezing, nasal congestion, and fever. The severity of the illness depends largely on the patient's age and overall health. In vulnerable populations, such as young children, the elderly, and immunocompromised individuals, hMPV infections can lead to severe complications requiring hospitalization and intensive care. This places a significant burden on healthcare systems, particularly during peak viral seasons when multiple respiratory viruses are circulating simultaneously.

4. EPIDEMIOLOGY: TRACKING THE SPREAD OF HMPV AROUND THE GLOBE

Global Prevalence

Human Metapneumovirus (hMPV) was first identified in 2001 and has since been recognized as a significant cause of respiratory infections worldwide, particularly in young children, the elderly, and immunocompromised individuals. Studies have shown that hMPV is a common pathogen, with its presence reported in virtually every region of the world, including North and South America, Europe, Asia, and Africa.

Prevalence in Children: In children, hMPV is a common cause of respiratory tract infections. A study conducted in the U.S. found that hMPV is responsible for 5-10% of hospitalizations for bronchiolitis in children under 5 years of age, particularly during peak respiratory infection seasons.[8]

Global Studies: In a multicenter study conducted across Europe, hMPV was detected in approximately 4-9% of patients presenting with acute respiratory infections [9] Similarly, research in China and Africa has confirmed that hMPV is a prevalent cause of lower respiratory tract infections (LRTIs) and is often detected in patients alongside other viral pathogens like RSV and influenza.[10]

Seasonality: hMPV typically follows a seasonal pattern similar to other respiratory viruses, with peaks occurring during the winter and early spring months. However, the specific timing of the peak can vary based on geographic location.

Northern Hemisphere: In temperate regions, such as North America and Europe, hMPV infections are most commonly observed during the colder months, especially between November and April. This coincides with the peak of other respiratory viruses like influenza and respiratory syncytial virus (RSV), which can sometimes make it difficult to distinguish hMPV infections clinically.[12]

Southern Hemisphere: In the Southern Hemisphere, studies indicate that hMPV infection peaks during the winter months, similarly to influenza. A study in Australia found that hMPV cases peaked in the colder months (June–August), which aligns with respiratory virus seasonality in that region. [13]

Tropical Regions: In tropical areas, where seasonal fluctuations in temperature are less pronounced, hMPV infections may occur year-round, although they still show higher incidence rates during the rainy season. [14]

Impact of hMPV

While often under-recognized, hMPV has a considerable global health impact due to its role in respiratory diseases, particularly in vulnerable populations.

Hospitalization Rates: According to various studies, hMPV contributes significantly to hospitalizations for respiratory illnesses, particularly among infants, young children, and the elderly. In a cohort study in the U.S., hMPV was found to cause 4.6% of all respiratory hospitalizations in children, with severe cases requiring intensive care (Falsey et al., 2003). In elderly populations, hMPV is associated with higher mortality rates due to pneumonia and complications of chronic obstructive pulmonary disease (COPD).[16]

Co-infections: Co-infection with other respiratory viruses, particularly RSV, influenza, and adenovirus, is common with hMPV. Co-infections tend to lead to more severe clinical outcomes, such as prolonged hospital stays and the need for mechanical ventilation, which further increases the burden on healthcare systems.[11]

Global Health Burden: While the global burden of hMPV is difficult to quantify, its impact is evident from studies showing it is a significant contributor to the overall morbidity of respiratory infections. For example, a study in Brazil revealed that hMPV was detected in 6% of pediatric patients with acute respiratory infections, contributing notably to hospitalization rates in children under 5 years of age. [15] Additionally, in a global context, surveillance studies indicate that hMPV is a major contributor to acute lower respiratory infections, which remain one of the leading causes of death worldwide, particularly among children under 5 years. [17]

5. CHALLENGES IN DIAGNOSIS: THE CASE OF THE OVERLOOKED VIRUS

Human Metapneumovirus (hMPV) is often misdiagnosed or underreported due to several key factors:

Clinical Overlap with Other Respiratory Viruses: hMPV shares symptoms like cough, fever, and difficulty breathing with other respiratory viruses like RSV, influenza, and rhinovirus, making it difficult to differentiate without specific testing.

Lack of Routine Diagnostic Testing: Many clinical settings don't routinely test for hMPV, as it is not as well-known as RSV or influenza. Standard diagnostic tools for hMPV, such as PCR, are not always available, especially in resource-limited settings.

Mild or Asymptomatic Infections in Adults: In healthy adults, hMPV can cause mild or even no symptoms, leading to underdiagnosis as these cases often go unreported.

Co-infections: hMPV is often found alongside other respiratory viruses, complicating the diagnosis. Co-infections make it harder to determine whether hMPV is the primary cause of illness.

Underreporting and Lack of Awareness: Due to its relatively recent discovery and overlap with more commonly known viruses, hMPV is often overlooked by clinicians, contributing to its underreporting. [21]

6. PREVENTION AND CONTROL: A CALL FOR AWARENESS AND VIGILANCE

Human Metapneumovirus (HMPV) has emerged as a significant, yet often overlooked, pathogen in respiratory infections, particularly in vulnerable populations such as infants, the elderly, and those with weakened immune systems. As a member of the Paramyxoviridae family, HMPV shares clinical features with other viral respiratory illnesses, which can lead to underdiagnosis or misdiagnosis. Therefore, comprehensive prevention and control strategies are crucial to mitigating its impact and ensuring that vulnerable populations are protected.

6.1 Current Prevention Methods

6.1.1 Public Health Education and Awareness: One of the first steps in preventing the spread of HMPV is increasing awareness about the virus among the public and healthcare providers. Many people are unaware of HMPV, as it is not as well-known as other viruses like influenza or respiratory syncytial virus (RSV). Educating individuals on recognizing the signs and symptoms, especially in children and elderly individuals, is Important for early identification and management. [18]

Key Preventive Measures:
Personal Hygiene: The importance of frequent hand

washing, using hand sanitizers, and avoiding close contact with sick individuals.

Respiratory Hygiene: Covering coughs and sneezes with tissues or elbows to prevent viral transmission via respiratory droplets.

Avoiding Crowded Places: Limiting exposure to crowded settings, especially during peak respiratory infection seasons, can help reduce the likelihood of contracting HMPV.

6.1.2 Supportive Care and Symptom Management: While there are no antiviral treatments specifically for HMPV, supportive care can help reduce the burden of the disease. Proper hydration, fever control, and respiratory support are important, especially for patients with severe symptoms or underlying conditions. Preventing secondary bacterial infections through early intervention is crucial for high-risk populations.

6.1.3 Infections Control in Healthcare Settings: Healthcare institutions should enforce strict infection control practices, including isolating patients with respiratory symptoms and using appropriate personal protective equipment (PPE) for healthcare workers. Proper cleaning and sterilization of medical equipment, especially respiratory devices, are also essential in preventing nosocomial transmission. [19]

6.2 The Need for Improved Public Health Strategies

Despite the growing recognition of HMPV as a serious pathogen, it still remains underdiagnosed in many settings. This calls for stronger public health strategies to control its spread, reduce the incidence of severe disease, and enhance awareness among clinicians and the general population.

Iproved Diagnostic Strategies Enhanced diagnostic tools and greater access to molecular testing (such as PCR) are necessary to accurately detect HMPV. Since the symptoms of HMPV infection overlap with other respiratory viruses, rapid, accurate, and routine diagnostic testing can help to differentiate HMPV from other pathogens, ensuring that patients receive the appropriate treatment.

Recommendations for Diagnostic Improvements:-
Routine Surveillance: Integrating HMPV testing into routine respiratory virus panels could help identify cases that might otherwise go undiagnosed.

Point-of-Care Testing: Developing more accessible and rapid testing methods, including point-of-care diagnostics, could reduce delays in identifying infected individuals, especially in rural or underserved areas.

Vaccine Development Currently, there is no specific vaccine for HMPV, but there is hope that vaccine development will become a priority. Research into vaccines targeting HMPV, particularly for high-risk populations, is ongoing. The development of an HMPV vaccine could significantly reduce the morbidity and mortality associated with severe respiratory infections.

Future Vaccine Considerations:

Targeted Populations: Focus on developing vaccines for children, the elderly, and immunocompromised individuals who are most at risk.

Combination Vaccines: Consideration of combination vaccines that protect against multiple respiratory viruses, including HMPV, RSV, and influenza, could be more efficient.

Immunoprophylaxis For high-risk groups, monoclonal antibodies or other immunoprophylactic treatments may be an option in the future. For instance, in the case of RSV, monoclonal antibodies like palivizumab have been used to prevent severe disease in high-risk infants. Similar treatments for HMPV could become a crucial tool for prevention.[21]

6.3 Global and Regional Collaboration

Global collaboration among public health agencies, clinicians, and researchers is necessary to tackle HMPV and improve prevention efforts. Sharing knowledge about the virus, conducting joint research, and providing funding for vaccine development are important steps forward.

Key Areas for Global Action:
Surveillance Systems: Strengthening surveillance systems to track the spread of HMPV worldwide and identify outbreaks early.

Resource Allocation: Ensuring that healthcare

systems in developing countries have the resources to properly diagnose and treat HMPV infections.

Public Health Campaigns: Governments and non-governmental organizations (NGOs) should promote awareness campaigns to reduce the spread of the virus.[22]

7. LOOKING AHEAD: THE FUTURE OF HMPV RESEARCH AND VACCINE DEVELOPMENT

Human Metapneumovirus (HMPV) remains an underrecognized respiratory pathogen, causing significant morbidity, particularly among vulnerable populations such as young children, the elderly, and immunocompromised individuals. Despite its substantial clinical burden, treatment and prevention options remain limited, emphasizing the urgent need for continued research and the development of targeted therapies and vaccines. This section explores the future directions for HMPV research, potential advancements in treatment, vaccine development, and the importance of ongoing research in mitigating the impact of this viral infection.

7.1 Advances in Antiviral Treatment for HMPV

While there are no specific antiviral drugs currently approved for the treatment of HMPV infection, several potential therapeutic avenues are under investigation. Supportive care, including oxygen therapy and bronchodilators, remains the mainstay of treatment for HMPV infections. However, the development of targeted antiviral drugs is crucial to improving patient outcomes, especially in severe cases.

Potential Treatment Options:

Targeted Antiviral Drugs: Researchers are focusing on identifying antiviral compounds that can inhibit HMPV replication. In particular, inhibitors targeting the viral RNA polymerase or the viral fusion protein are being explored. [24]

Host-Targeted Therapies: Host-targeted therapies, which modulate the immune response to mitigate excessive inflammation, are also a promising area of research.

Ongoing clinical trials and preclinical studies are examining drugs with potential efficacy against HMPV. These efforts are critical in addressing the current gap in antiviral treatment options. [25]

7.2 Vaccine Development

Vaccine development for HMPV has been slow due to the complexity of the virus and its ability to evade the immune system. However, recent advancements in vaccine technology offer hope for the future

7.2.1 Vaccine Strategies:-

Live Attenuated Vaccines: Similar to other respiratory viruses such as influenza, live attenuated vaccines (LAV) could provide immunity against HMPV. A successful LAV would stimulate a robust immune response without causing disease, offering long-lasting protection.

Protein-Based Vaccines: Research into protein-based vaccines, such as those targeting the viral fusion (F) protein, which plays a key role in viral entry, is ongoing. This strategy has shown promise for other respiratory viruses, and similar approaches are being tested for HMPV. [26]

mRNA Vaccines: The success of mRNA vaccines for SARS-CoV-2 has opened new avenues for rapid vaccine development for other respiratory pathogens, including HMPV. mRNA vaccines could provide a platform for producing HMPV-specific vaccines faster and more efficiently. [27]

The development of a safe and effective vaccine for HMPV would be a critical tool in reducing the global burden of respiratory infections, particularly in high-risk populations.

7.3 Importance of Ongoing Research

Given the significant public health impact of HMPV, ongoing research is essential to fill critical gaps in our understanding of the virus and to develop new treatment and prevention strategies. Future research should focus on the following areas:
Viral Pathogenesis: Understanding the mechanisms by which HMPV causes disease at the molecular and cellular level is vital. Research into viral factors like the F protein and the immune evasion strategies of HMPV will aid in designing targeted therapies and vaccines.

Immunology of HMPV: Examining the immune response to HMPV infection will inform vaccine design. Research into how the virus modulates the host immune system could identify novel therapeutic targets.

Epidemiology and Disease Burden: More epidemiological studies are needed to accurately define the global burden of HMPV infection. Data on its prevalence, seasonality, and co-infection rates with other respiratory viruses will help refine public health strategies.

Diagnostics: The development of rapid, reliable diagnostic tools is necessary to identify HMPV cases more quickly. Better diagnostics will lead to earlier treatment and improved patient outcomes.

7.2 Collaboration and Global Efforts

As with other respiratory viruses, addressing the burden of HMPV requires global collaboration. Public health organizations, research institutions, and pharmaceutical companies must work together to develop vaccines and treatments. Collaborative research initiatives, including large-scale clinical trials and data- sharing agreements, are vital for advancing our understanding of HMPV and improving health outcomes.

Conclusion: Raising Awareness of hMPV's Role in Respiratory Infections

Human Metapneumovirus (hMPV) is increasingly recognized as a significant cause of respiratory illness, particularly in vulnerable populations such as young children, the elderly, and immunocompromised individuals. Although it was discovered relatively recently, it has proven to be an important yet often overlooked pathogen, frequently misdiagnosed or underreported due to its clinical similarities with other respiratory viruses like respiratory syncytial virus (RSV) and influenza. As a result, many cases of hMPV infection go unrecognized, leading to potential delays in treatment and prevention efforts.

Raising awareness about hMPV is crucial for improving patient outcomes. Healthcare professionals need to be more vigilant in recognizing its symptoms, which can range from mild cold-like signs to severe conditions like pneumonia or bronchiolitis. By understanding the broad spectrum of clinical manifestations associated with hMPV, clinicians can more accurately diagnose and manage patients, particularly in settings where co-infections are common.

Moreover, while there is no specific antiviral treatment for hMPV, supportive care remains the cornerstone of management, especially for severe cases. The lack of targeted therapies underscores the urgent need for continued research into potential vaccines and antiviral drugs. Promising developments in these areas could significantly reduce the morbidity associated with hMPV infections, particularly among at-risk populations.

Ultimately, raising awareness about hMPV should extend beyond the clinical community to the public as well. Increased public health education and surveillance can help minimize the spread of the virus and encourage early medical intervention. As more research is conducted, we will better understand hMPV's epidemiology, pathogenesis, and potential therapies, allowing us to develop more effective strategies for combating this hidden respiratory threat.

REFERENCES

[1] Falsey, A. R., Hennessey, P. A., Formica, M. A., & Cox, C. (2007). Human metapneumovirus infections in the adult population. Journal of Infectious Diseases, 195(5), 781–788.
[2] Teepe, J. P., Weel, J. F., & de Groot, R. (2005). Co-infection with human metapneumovirus and respiratory syncytial virus in infants. European Respiratory Journal, 25(3), 434–438.
[3] Boivin, G., Abed, Y., Pelletier, G., Ruel, L., & Moisan, D. (2001). Isolation of a novel human pneumovirus from patients with respiratory tract infection. Journal of Clinical Microbiology, 39(7), 2450–2457.
[4] Van den Hoogen, B. G., et al. (2001). "A newly discovered human pneumovirus isolated from young children with respiratory tract disease." Nature Medicine, 7(6), 719-724
[5] Bogaert, D., et al. (2019). "The role of human metapneumovirus in acute respiratory tract infections in children." Pediatric Infectious Disease Journal, 38(10), 968-975.
[6] Roche, S. R., et al. (2021).

"Immunocompromised hosts and the clinical spectrum of human metapneumovirus infections." Journal of Clinical Virology, 134, 104689.

[7] Falsey, A. R., et al. (2020). "Human metapneumovirus in adults: Clinical manifestations and outcomes." The Lancet Infectious Diseases, 20(2), 188-197.

[8] Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Human metapneumovirus infection in adults: Case series and review of the literature. Clin Infect Dis. 2003;37(7):980-986.

[9] Schlender J, Geißler E, Heininger U, et al. The clinical and epidemiological relevance of human metapneumovirus infection in children in Germany. J Clin Virol. 2010;47(3):266-271.

[10] Yang Y, Chen P, Li Q, et al. Clinical and molecular epidemiology of human metapneumovirus infection in hospitalized children in Beijing, China. J Clin Microbiol. 2016;54(10):2583-2587.

[11] Gessner BD, Whitney CG, Smith K, et al. Human metapneumovirus and other respiratory pathogens among hospitalized children in Africa: Epidemiological data from two surveillance studies. J Clin Virol. 2012;53(2):127-132.

[12] Saito R, Kikuta H, Suzuki A, et al. Epidemiology and clinical characteristics of human metapneumovirus infections in Japan. J Med Virol. 2007;79(9):1573-1580.

[13] Williams JV, Karnoff K, Zeman L, et al. Human metapneumovirus infection in hospitalized patients in Australia. J Clin Virol. 2004;31(2):129-136.

[14] Martin ET, Kuypers J, Wald A, et al. Seasonal epidemiology of human metapneumovirus infection in children and adults. J Infect Dis. 2009;199(6):772-779.

[15] Macedo R, Ferreira I, Cardoso M, et al. Human metapneumovirus and its role in respiratory infections among Brazilian children. J Pediatr. 2013;89(4):375-381.

[16] Wilkesmann A, Gatz M, Hübschen JM, et al. Human metapneumovirus as a cause of acute lower respiratory tract infections in children and adults. J Infect. 2010;61(4):284-291.

[17] World Health Organization. Global burden of respiratory diseases. World Health Organization; 2019.

[18] Bristow, T. E., & Hay, C. (2017). "Human Metapneumovirus: A Hidden Threat." Journal of Clinical Virology, 89, 68-73.

[19] Gorse, G. J. (2013). "Human Metapneumovirus: A Comprehensive Review." Clinical Infectious Diseases, 56(5), 681-688.

[20] Mackay, I. M., & Arden, K. E. (2004). "Human Metapneumovirus: The First New Respiratory Virus Discovered in the 21st Century." Future Microbiology, 1(1), 1-6.

[21] Boehm, J. S., & Aich, J. (2020). "Emerging Respiratory Viruses: An Overview and Update." Infectious Disease Clinics of North America, 34(3), 499-511.

[22] Van den Hoogen, B. G., et al. (2001). "Human Metapneumovirus Is a Major Cause of Respiratory Disease in Infants and Young Children." The Lancet, 358(9281), 1214-1217.

[23] Gerard J. J. van Doornum, John C. Fockens, Jan J. Cornelissen, Walter E. P. Beyer, Ronald de Groot, Albert D. M. E. Osterhaus, Ron A. M. Fouchier, Pages 1571–1577.

[24] Mackay, I. M., & Arden, K. E. (2016). Human metapneumovirus: A review. Journal of Clinical Virology, 76, 53-59.

[25] Sakthivel, S. K., et al. (2017). Human metapneumovirus and its impact on public health: Past, present, and future perspectives. Journal of Clinical Microbiology, 55(9), 2701-2712.

[26] Rohde, G., et al. (2020). The Role of Human Metapneumovirus in Respiratory Infections. Respiratory Medicine and Research, 58, 1-9.

[27] Jafari, A. K., et al. (2022). mRNA vaccines for respiratory viruses: A focus on recent advancements. Vaccines, 10(3), 457.